---
title: HTS FGFR3 Small Molecule Drug Discovery Case Study Series
---

![FGFR3 header](https://info.xtalpi.com/hubfs/FGFR3%20header.png "FGFR3 header")

Case Study: How XtalPi Used Diversity Library of 80K Compounds to Find Hits Targeting FGFR3 

Mutations in Fibroblast Growth Factor Receptor 3 (FGFR3) are linked to various cancers. In an effort to selectively target FGFR3, XtalPi sought to identify novel scaffolds using our curated high-throughput screening (HTS) diversity library.

 

Our Key Results:

- Discovery of **15 potent hit compounds**, each exhibiting biochemical potency with IC50 values below 10 μM.
- **Identified three hit series** which possessed novel scaffolds that are distinct from those of known FGFR3 inhibitors, providing new avenues for selectively targeting the protein.

<https://www.linkedin.com/company/xtalpi/> <https://www.xtalpi.com/en> [mailto:bd@xtalpi.com](mailto:bd@xtalpi.com)